Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. EBM Technologies's EBITDA for the
three
months ended in Jun. 2026 was NT$-17.4 Mil. EBM Technologies's Revenue for the
three
months ended in Jun. 2026 was NT$35.7 Mil. Therefore, EBM Technologies's EBITDA margin for the quarter that ended in Jun. 2026 was -48.58%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
EBM Technologies EBITDA Margin % Related Terms
EBM Technologies EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for EBM Technologies's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:8409 vs VEEV, BTSG, HQY: EBITDA Margin % Comparison
For the Health Information Services subindustry, EBM Technologies's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EBM Technologies EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, EBM Technologies's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where EBM Technologies's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBM Technologies (ROCO:8409) has a EBITDA Margin % of -48.58% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EBM Technologies and its competitors. According to the industry distribution chart, EBM Technologies ranks #205 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 30.6%.
Is EBM Technologies' EBITDA Margin % too high?
EBM Technologies' current EBITDA Margin % is -48.58%. Based on the distribution chart, EBM Technologies ranks #205 out of 669 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, EBM Technologies has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does EBM Technologies' EBITDA Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, EBM Technologies ranks #205 out of 669 companies for EBITDA Margin %. This puts EBM Technologies in the upper half of its industry. The industry median EBITDA Margin % is 10.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.30, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on EBM Technologies and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EBM Technologies's current EBITDA Margin % is -48.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EBM Technologies stock overvalued right now?
Based on GuruFocus' analysis, EBM Technologies (ROCO:8409) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$25.21, compared to a current price of NT$17.90 — trading 29% below its estimated fair value. The current EBITDA Margin % is -48.58%. EBM Technologies' overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For EBM Technologies (ROCO:8409), the current EBITDA Margin % is -48.58% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EBM Technologies (ROCO:8409) Overvalued in 2026?
Based on GuruFocus' analysis, EBM Technologies stock appears to be undervalued.
The current stock price of NT$17.90 is trading 29% below its estimated GF Value™ of NT$25.21.
GuruFocus considers EBM Technologies to be Modestly Undervalued.
Key valuation signals for ROCO:8409:
EBITDA Margin %: -48.58%
GF Value™: NT$25.21 vs. price of NT$17.90 (29% below fair value)
No single metric tells the full story. See the ROCO:8409 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EBM Technologies Inc is engaged in picture archiving and communication systems. Its products include EBM diagnostic and reviewing station, EBM storage and utility server, and EBM breast imaging for PACS. The company develops and markets medical information technology solutions; and provides to the health sector.
67GF Score
Get the complete analysis for ROCO:8409
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8409 has been successfully added to your 
